MDACC Study No:2006-0706 ( NCT No: NCT00413166)
Title:Treatment of APL with all-trans retinoic acid, and arsenic +/- idarubicin
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Arsenic Trioxide; ATRA
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if starting arsenic
trioxide (ATO) therapy on Day 10 rather than Day 1 is more effective in
treating patients with newly-diagnosed APL. Researchers also want to learn if
theophylline can help to control APL.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Arsenic Trioxide
Treatment Location:MDACC + Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Twice weekly for 1 month, then every 3 - 6 months.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults